

bs-1023R**[Primary Antibody]****G-CSF/CSF3 Rabbit pAb****BioSS**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

— DATASHEET —

Host: Rabbit Clonality: Polyclonal GeneID: 1440 Target: G-CSF/CSF3 Immunogen: KLH conjugated synthetic peptide derived from human CSF3: 155-198/207. Purification: affinity purified by Protein A Concentration: 1mg/ml Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. Background: Granulocyte-colony stimulating factor (G-CSF) is a growth factor and an essential cytokine belonging to the CSF family of hormone-like glycoproteins that regulate haematopoietic cell proliferation and differentiation. G-CSF was isolated initially as a factor supporting the growth of colonies of granulocytes in soft agar cultures. Cells of the monocyte/macrophage lineage are among the most prominent sources of G-CSF, but this factor can also be produced by normal cells of mesodermal origin, including vascular endothelial cells, fibroblasts, and mesothelial cells. Production of G-CSF can be induced in vitro in these cells by a wide variety of stimulatory agents, including LPS, TNF, IL-1, IL-3, IL-4, and IFN-Gamma. G-CSF is likely to play a role in the basal regulation of neutrophil production, and also functions as a primary regulatory factor controlling the neutrophil response to inflammatory stimuli. Furthermore, G-CSF exhibits other biological activities besides the proliferative effects, since G-CSF appears to modulate the distribution of neutrophils and progenitor cells within the body.	Isotype: IgG SWISS: P09919 Applications: IHC-P (1:100-500) IHC-F (1:100-500) IF (1:100-500) Reactivity: Human, Mouse (predicted: Rat, Pig, Sheep, Cow) Predicted MW.: 19 kDa Subcellular Location: Secreted
---	--

— VALIDATION IMAGES —

Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (G-CSF) Polyclonal Antibody, Unconjugated (bs-1023R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (human kidney tissue); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (CSF3) Polyclonal Antibody, Unconjugated (bs-1023R) at 1:400 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.

— SELECTED CITATIONS —

- **[IF=7.3]** Kang Zhi-Ying. et al. Heterogeneity of Immune Cells and Their Communications Unveiled by Transcriptome

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Profiling in Acute Inflammatory Lung Injury. FRONT IMMUNOL. 2024 Apr;15: IHC ;Mouse. 38745657

- **[IF=6.529]** Ting Shang. et al. The combination of four main components in Xuebijing injection improved the preventive effects of Cyclosporin A in acute graft-versus-host disease mice by protecting intestinal microenvironment. Biomed Pharmacother. 2022 Apr;148:112675 WB,IHC ;Mouse. 35183993
- **[IF=5.085]** Yi Yang. et al. $\gamma\delta$ T/Interleukin-17A Contributes to the Effect of Maresin Conjugates in Tissue Regeneration 1 on Lipopolysaccharide-Induced Cardiac Injury. Front Immunol. 2021; 12: 674542 WB ;Mouse. 33981320
- **[IF=5.345]** Yuan SJ et al. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.J Nanobiotechnology. 2019 Oct 17;17(1):110. IHC ;Mouse. 31623629
- **[IF=5.177]** Wen-Chieh Liao. et al. CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment. Am J Cancer Res. 2021; 11(3): 812–826 WB,IHC ;Human. 33791155